Abstracts tagged "large vessel vasculitis"

Abstract Number: 2644 • 2019 ACR/ARP Annual Meeting
Ultrasound to Monitor Treatment Response in Large Vessel Giant Cell Arteritis
Anne Bull Haaversen¹, Viktoria Holt ², Shagaye Nabizadeh ², Annicken Slagsvold ² and Andreas P Diamantopoulos ³, ¹Martina Hansens Hospital, Sandvika, Norway, ²Martina Hansens Hospital, Bærum, Norway, ³Martina Hansens Hospital, SANDVIKA, Oslo, Norway
Background/Purpose: On ultrasound (US) examinations, large vessel vasculitis (LVV) has been reported to be present in up to 55% of Giant cell arteritis (GCA) patients.…
Abstract Number: 2646 • 2019 ACR/ARP Annual Meeting
Survival of Large Vessel Giant Cell Arteritis in Northern Italy During a 26-year Period : No Correlation with Demographical, Clinical, Laboratory and Imaging Data
Luigi Boiardi¹, Mariagrazia Catanoso ², Giovanna Restuccia ³, Francesco Muratore ³, Pierluigi Macchioni ⁴ and Carlo Salvarani ⁵, ¹Division of Rheumatology, Azienda Unita' Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, ²Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, ITALY, Reggio Emilia, Italy, ³Division of Rheumatology, Azienda Unita’ Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁴Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, ⁵Division of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy
Background/Purpose: To investigate the relationship between demographical, clinical, laboratory and imaging data and survival in patients with large vessel giant cell arteritis (LVGCA) in a…
Abstract Number: 2664 • 2019 ACR/ARP Annual Meeting
Color Doppler Ultrasound for the Diagnosis of Giant Cell Arteritis in Montreal: A Canadian Single Center Experience
Jean-Paul Makhzoum¹, Meriem Belhocine ¹, Michelle Goulet ¹, Maxime Rheaume ¹, Tara Starnino ², Stephanie Ducharme-Benard ², Guillaume Febrer ³, Yves Troyanov ⁴, Nathalie Routhier ⁵, Rosalie-Selene Meunier ⁵, Isabelle Chagnon ⁵, Michel Laurier ⁵, Maggy Helou ⁵, Nathalie Morency ⁶ and Anne-Marie Mansour ¹, ¹Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ²Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, Canada, ³Vascular Surgery, Department of Surgery, Hopital du Sacre-Coeur de Montreal, Montreal, Canada, ⁴Division of Rheumatology, Department of Medicine, Hôpital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁵Internal Medicine, Department of Medicine, Hopital du Sacre-Coeur de Montreal, Montreal, Canada, ⁶Division of Rheumatology, Department of Medicine, Montreal, Canada
Background/Purpose: Giant Cell Arteritis (GCA) remains challenging to diagnose as false negative temporal artery biopsy (TAB) can occur. Color doppler ultrasonography (CDUS) of the temporal,…
Abstract Number: 2673 • 2019 ACR/ARP Annual Meeting
Presentation and Management of Giant Cell Arteritis in a Real-World Setting (Artemis Study)
Alfred Mahr¹, Eric Hachulla ², Hubert de BOYSSON ³, Nassim Guerroui ⁴, Emmanuel Héron ⁵, Stéphane Vinzio ⁶, Jonathan Broner ⁷, François-Xavier Lapebie ⁸, Martin Michaud ⁹, Laurent Sailler ⁸, Thierry Zenone ¹⁰, Mohamed Djerad ¹¹, Mathieu Jouvray ¹², Emilie Shipley ¹³, Nathalie Tieulie ¹⁴, Isabelle Idier ¹⁵, Marc Paccalin ¹⁶ and Valérie Devauchelle Pensec ¹⁷, ¹Hospital Saint-Louis, University Paris Diderot, Paris, France, ²Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France, ³University Hospital of Caen, Caen, France, ⁴European Hospital of Marseille, Marseille, France, ⁵Quinze-Vingt Hospital, Paris, France, ⁶GHM Grenoble, Grenoble, France, ⁷University Hospital of Nîmes, Nîmes, France, ⁸University Hospital of Toulouse, Toulouse, France, ⁹Joseph Ducuing Hospital, Toulouse, France, ¹⁰Hospital of Valence, Valence, France, ¹¹Hospital of Nevers, Nevers, France, ¹²Hospital of Arras, Arras, France, ¹³Hospital of Dax, Dax, France, ¹⁴University Hospital of Nice, Nice, France, ¹⁵Chugai Pharma France, Paris La Défense, France, ¹⁶University Hospital of Poitiers, Poitiers, France, ¹⁷University Hospital of Brest, Brest, France
Background/Purpose: We have few real-world data on the natural history and care of patients with giant cell arteritis (GCA). The objective of this observational study…
Abstract Number: 819 • 2018 ACR/ARHP Annual Meeting
Use of Takayasu Arteritis Damage Score (TADS) to Measure Damage in Takayasu Arteritis
Sivakumar Mambakkam Rajappa¹ and Krishnamurthy Venkataraman², ¹Rheumatology and Immunology, GLB Hospitals, Chennai, India, ²Rheumatology, Apollo Speciality Hospitals, Chennai, India
Background/Purpose: Takayasu Arteritis (TA) in India frequently present with complications, indicating the need for a specific damage index to capture the accumulation of disease-related scars…
Abstract Number: 2196 • 2018 ACR/ARHP Annual Meeting
Kinetics of Tissue-Specific Distribution of 18f-Fluorodeoxyglucose in Positron Emission Tomography in Large Vessel Vasculitis
Joel S. Rosenblum¹, Kaitlin Quinn², Mark A. Ahlman³ and Peter C. Grayson⁴, ¹NIAMS, National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, ²Systemic Autoimmunity Branch, NIAMS, Bethesda, MD, ³Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, ⁴National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD
Background/Purpose: 18F-fluorodeoxyglucose (FDG) PET may be used to quantify vascular inflammation in large-vessel vasculitis (LVV). Quantitative analysis of arterial FDG uptake has not been standardized. Delayed…
Abstract Number: 2746 • 2018 ACR/ARHP Annual Meeting
Tocilizumab Monotherapy for Large Vessel Vasculitis: Results of 104-Week Treatment of a Prospective, Single-Center, Open Study
Shuntaro Saito, Ayumi Okuyama, Yusuke Okada, Akiko Shibata, Ryota Sakai, Kentaro Chino, Takahiko Kurasawa, Tsuneo Kondo, Hirofumi Takei and Koichi Amano, Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
Background/Purpose: To evaluate the efficacy and safety of tocilizumab (TCZ) monotherapy for Large Vessel Vasculitis (LVV), including Takayasu arteritis (TAK) and Giant cell arteritis (GCA).…
Abstract Number: 2759 • 2018 ACR/ARHP Annual Meeting
Effect of Specific Treatments on Clinical, Serologic, and Imaging Assessments of Disease Activity in Large-Vessel Vasculitis
Shubhasree Banerjee¹, Kaitlin Quinn², Katherine B. Gribbons³, Joel S. Rosenblum⁴, Ali Civelek⁵, Elaine Novakovich⁶, Armin Bagheri¹, Peter A. Merkel⁷, Mark A. Ahlman⁸ and Peter C. Grayson⁹, ¹Systemic Autoimmunity Branch, NIAMS, NIH, Bethesda, MD, ²Systemic Autoimmunity Branch, NIAMS, Bethesda, MD, ³Systemic Autoimmunity Branch, National Institute of Arthritis and Skin and Musculoskeletal Disease, Bethesda, MD, ⁴NIAMS, National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, ⁵National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD, ⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, ⁹National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD
Background/Purpose: Disease activity in large vessel vasculitis (LVV) is traditionally assessed by clinical and serologic (ESR, CRP) parameters. Imaging assessment, including 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET),…
Abstract Number: 2778 • 2018 ACR/ARHP Annual Meeting
High Prevalence of Vascular Surgery and Autoimmune Comorbidity in Takayasu Arteritis
Tsuyoshi Shirai¹, Tomoyuki Muto², Yuko Shirota¹, Hiroshi Fujii¹, Tomonori Ishii³ and Hideo Harigae¹, ¹Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ²Tohoku University Graduate School of Medicine, Sendai, Japan, ³Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan
Background/Purpose: Large vessel vasculitis (LVV) is the arteritis in aorta and its major branches, and classified into Takayasu arteritis (TAK) and giant cell arteritis (GCA).…
Abstract Number: 2737 • 2017 ACR/ARHP Annual Meeting
Pulmonary Manifestations of Primary Systemic Vasculitides
Jean-Paul Makhzoum¹, Raashid Luqmani², Richard A. Watts³, Anthea Craven⁴, Peter A. Merkel⁵ and Christian Pagnoux⁶, ¹Rheumatology, Vasculitis Clinic, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ³Rheumatology Department, The Ipswich Hospital, Ipswich, Great Britain, ⁴Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, Oxford University Hospitals, Oxford, United Kingdom, ⁵Division of Rheumatology, University of Pennsylvania; Perelman School of Medicine, Philadelphia, PA, ⁶Rheumatology-Vasculitis clinic, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Pulmonary involvement in systemic primary vasculitides is diverse and occurs with variable incidence depending on the type of vasculitis. This study aimed to describe…
Abstract Number: 102 • 2017 ACR/ARHP Annual Meeting
Incorporating Temporal Artery Ultrasound in a UK District General Hospital with No Prior Colour Doppler Sonography Service: An Encouraging Preliminary Analysis
Othman Kirresh¹, Chintu Gademsetty² and Charles Li¹, ¹Rheumatology, NHS Royal Surrey County Hospital, Surrey, United Kingdom, ²Radiology, NHS Royal Surrey County Hospital, Surrey, United Kingdom
Background/Purpose: Temporal Arteritis (TA) is the most common large vessel vasculitis, affecting adults over the age of 50. It is associated with significant morbidity due…
Abstract Number: 785 • 2017 ACR/ARHP Annual Meeting
Longitudinal Angiographic Findings in Patients with Takayasu’s Arteritis
Antoine G. Sreih¹, Tanaz A. Kermani², David Cuthbertson³, Simon Carette⁴, Lindsy J. Forbess⁵, Nader A. Khalidi⁶, Curry L. Koening⁷, Carol A. McAlear⁸, Paul A. Monach⁹, Larry W. Moreland¹⁰, Christian Pagnoux¹¹, Philip Seo¹², Robert F. Spiera¹³, Kenneth J. Warrington¹⁴, Steven R. Ytterberg¹⁴, Carol A. Langford¹⁵ and Peter A. Merkel^16,17, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Division of Rheumatology, University of California, Los Angeles, CA, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Medicine, Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁶Rheumatology, McMaster University, Hamilton, ON, Canada, ⁷Rheumatology, University of Utah, Salt Lake City, UT, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Boston University School of Medicine, Boston, MA, ¹⁰Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹¹Rheumatology-Vasculitis clinic, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹²Medicine, Johns Hopkins University, Baltimore, MD, ¹³Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁴Rheumatology, Mayo Clinic, Rochester, MN, ¹⁵Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹⁶Biostatistics, Epidemiology, and Bioinformatics, University of Pennsylvania, Philadelphia, PA, ¹⁷Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose : Longitudinal data on the type, progression, and predictors of arterial lesions in patients with Takayasu’s arteritis (TAK) is limited. This study aimed to…
Abstract Number: 788 • 2017 ACR/ARHP Annual Meeting
Mast Cell Mediated Inhibition of Systemic IL-6 in candida Albicans Water-Soluble Fraction (CAWS) Induced Model of Large Vessel Vasculitis
Mingcai Zhang¹, Mehrdad Maz², Don Smith³, Noriko Miura⁴, Naohito Ohno⁵, Kottarappat Dileepan⁶ and Jason Springer⁷, ¹Department of Orthopedics, University of Kansas Medical Center, Kansas City, KS, ²Allergy, Clinical Immunology, and Rheumatology, Division of Allergy, Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, ³University of Kansas Medical Center, Kansas City, KS, ⁴School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan, ⁵Tokyo University of Pharmacy and Lift Sciences, Tokyo, Japan, ⁶Department of Medicine, University of Kansas Medical Center, Kansas, KS, ⁷Department of Internal Medicine, Division of Allergy, Clinical Immunology, & Rheumatology, Kansas University Medical Center, Kansas City, KS
Background/Purpose: In forms of large vessel vasculitis (LVV) systemic IL-6 has been shown to follow disease activity. Furthermore, IL-6 inhibition is an effective treatment for…
Abstract Number: 795 • 2017 ACR/ARHP Annual Meeting
Characteristics and Treatment Outcomes of Giant Cell Arteritis with Large-Vessel Lesions in a Nationwide, Retrospective Cohort Study in Japan
Takahiko Sugihara¹, Hitoshi Hasegawa², Haruhito Uchida³, Hajime Yoshifuji⁴, Yoshikazu Nakaoka⁵, Yoshiko Watanabe⁶, Eisuke Amiya⁷, Masanori Konishi⁸, Yasuhiro Katsumata⁹, Yoshinori Komagata¹⁰, Taio Naniwa^11,12, Takahiro Okazaki¹³, Yoshiya Tanaka¹⁴, Tsutomu Takeuchi¹⁵, Masayoshi Harigai¹⁶, Yoshihiro Arimura¹⁷ and Mitsuaki Isobe^8,18, ¹Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ²Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan, ³Department of Chronic Kidney Disease and Cardiovascular Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ⁴Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵Osaka University Graduate School of Medicine, Osaka, Japan, ⁶First Department of Physiology, Kawasaki Medical School, Kurashiki, Japan, ⁷Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ⁸Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan, ⁹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁰First Dept. of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, ¹¹Division of Rheumatology, Dept of Internal Medicine,, Nagoya City University Hospital, Nagoya, Japan, ¹²Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ¹³Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ¹⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹⁶Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁷First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, ¹⁸Sakakibara Heart Institute, Tokyo, Japan
Background/Purpose: Giant cell arteritis (GCA) often affects aorta or its branches, but it is unclear whether the large-vessel (LV) lesions are associated with treatment outcomes.…
Abstract Number: 801 • 2017 ACR/ARHP Annual Meeting
PET-CT Findings and Clinical Outcomes in Takayasu Arteritis – Does 18F-Fluorodeoxyglucose Uptake in Arteries Predict Relapses?
Anna Larissa Faria Janes¹, Míriam Fang Castro¹, Bruna Savioli¹, Anne Elisabeth Diniz Arraes¹, Emilia Sato² and Alexandre W.S. Souza³, ¹Internal Medicine - Rheumatology Division, Universidade Federal de São Paulo - Escola Paulista de Medicina, São Paulo, Brazil, ²Rheumatology Division, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ³Rheumatology Div/Dept of Med, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil
Background/Purpose: PET-CT scan with 18F-Fluorodeoxyglucose (18F-FDG) has been frequently used as a tool to assess disease activity in Takayasu arteritis (TA) and increased 18F-FDG uptake…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].